Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma

Author： Homma Yuki Taniguchi Koichi Murakami Takashi Nakagawa Kazuya Nakazawa Masatoshi Matsuyama Ryusei Mori Ryutaro Takeda Kazuhisa Ueda Michio Ichikawa Yasushi Tanaka Kuniya Endo Itaru

Publisher： Springer Publishing Company

ISSN： 1068-9265

Source： Annals of Surgical Oncology, Vol.21, Iss.2, 2014-02, pp. : 670-676

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma

By Tinchon Christoph

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1231-1233

Informa Healthcare

Access to resources Recommend Favorite

Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis

By Xu C. Xue X. Liang N. Xu D. Liu F. Yu X. Zhang J.

Journal of Cancer Research and Clinical Oncology, Vol. 140, Iss. 4, 2014-04 ,pp. : 549-559

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer

By Irmscher Sabrina

Annals of Surgical Oncology, Vol. 15, Iss. 7, 2008-07 ,pp. : 2059-2060

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer

By Palmer Daniel

Annals of Surgical Oncology, Vol. 15, Iss. 7, 2008-07 ,pp. : 2061-2061

Springer Publishing Company

Access to resources Recommend Favorite

Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma: Improvements Needed in Population-Based Registries

By Miura John Evans Douglas Pappas Sam Gamblin T. Turaga Kiran

Annals of Surgical Oncology, Vol. 20, Iss. 13, 2013-12 ,pp. : 4338-4347

Springer Publishing Company

Access to resources Recommend Favorite